{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T21:18:51Z","timestamp":1792876731815,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00415-025-13230-w","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T08:05:58Z","timestamp":1751357158000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparative efficacy and safety of irreversible (rasagiline) and reversible (safinamide) monoamine oxidase inhibitors as add-on therapy for Parkinson\u2019s disease"],"prefix":"10.1007","volume":"272","author":[{"given":"Marwah Bintay","family":"Khalid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faizan","family":"Shahzad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momina Riaz","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Zain Ul","family":"Abedin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Hulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0685-8991","authenticated-orcid":false,"given":"Besher","family":"Shami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Ijlal","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"issue":"1","key":"13230_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cger.2019.08.002","volume":"36","author":"DK Simon","year":"2020","unstructured":"Simon DK, Tanner CM, Brundin P (2020) Parkinson disease epidemiology, pathology, genetics, and pathophysiology. Clin Geriatr Med 36(1):1\u201312","journal-title":"Clin Geriatr Med"},{"issue":"2","key":"13230_CR2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1176\/jnp.14.2.223","volume":"14","author":"J Parkinson","year":"2002","unstructured":"Parkinson J (2002) An essay on the shaking palsy 1817. J Neuropsychiatry Clin Neurosci 14(2):223\u2013236","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"13230_CR3","first-page":"4216452","volume":"2022","author":"O Kano","year":"2022","unstructured":"Kano O, Tsuda H, Hayashi A, Arai M (2022) Rasagiline as adjunct to levodopa for treatment of parkinson\u2019s disease: a systematic review and meta-analysis. Parkinsons Dis 2022:4216452","journal-title":"Parkinsons Dis"},{"issue":"1","key":"13230_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.14108","volume":"27","author":"R Balestrino","year":"2020","unstructured":"Balestrino R, Schapira AHV (2020) Parkinson disease. Eur J Neurol 27(1):27\u201342","journal-title":"Eur J Neurol"},{"issue":"4","key":"13230_CR5","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3390\/biom11040612","volume":"11","author":"FC Church","year":"2021","unstructured":"Church FC (2021) Treatment options for motor and non-motor symptoms of parkinson\u2019s disease. Biomolecules 11(4):612","journal-title":"Biomolecules"},{"key":"13230_CR6","volume":"4","author":"ME Mohammad","year":"2021","unstructured":"Mohammad ME, Vizcarra JA, Garcia X, Patel S, Margolius A, Yu XX et al (2021) Impact of behavioral side effects on the management of Parkinson patients treated with dopamine agonists. Clin Park Relat Disord 4:100091","journal-title":"Clin Park Relat Disord"},{"issue":"2","key":"13230_CR7","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3233\/JPD-212976","volume":"12","author":"YY Tan","year":"2022","unstructured":"Tan YY, Jenner P, Chen SD (2022) Monoamine oxidase-B inhibitors for the treatment of parkinson\u2019s disease: past, present, and future. J Parkinsons Dis 12(2):477\u2013493","journal-title":"J Parkinsons Dis"},{"issue":"4","key":"13230_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2217\/nmt-2020-0017","volume":"10","author":"T M\u00fcller","year":"2020","unstructured":"M\u00fcller T (2020) Safinamide in the treatment of Parkinson\u2019s disease. Neurodegener Dis Manag 10(4):195\u2013204","journal-title":"Neurodegener Dis Manag"},{"key":"13230_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/oso\/9780195171938.001.0001","volume-title":"The parkinson\u2019s disease treatment book","author":"JE Ahlskog","year":"2005","unstructured":"Ahlskog JE (2005) The parkinson\u2019s disease treatment book. Oxford University Press, New York NY"},{"issue":"20","key":"13230_CR10","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1056\/NEJM198911163212004","volume":"321","author":"Parkinson Study Group","year":"1989","unstructured":"Parkinson Study Group (1989) Effect of deprenyl on the progression of disability in early Parkinson\u2019s disease. N Engl J Med 321(20):1364\u20131371","journal-title":"N Engl J Med"},{"issue":"6","key":"13230_CR11","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/00002826-200011000-00005","volume":"23","author":"JM Rabey","year":"2000","unstructured":"Rabey JM, Sagi I, Huberman M, Melamed E, Korczyn A, Giladi N et al (2000) Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson\u2019s disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol 23(6):324\u2013330","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"13230_CR12","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/sj.bjp.0703826","volume":"132","author":"MB Youdim","year":"2001","unstructured":"Youdim MB, Gross A, Finberg JP (2001) Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 132(2):500\u2013506","journal-title":"Br J Pharmacol"},{"issue":"339","key":"13230_CR13","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"21","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 21(339):b2535\u2013b2535","journal-title":"BMJ"},{"issue":"366","key":"13230_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"28","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 28(366):l4898","journal-title":"BMJ"},{"issue":"1","key":"13230_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT (2021) Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods 12(1):55\u201361","journal-title":"Res Synth Methods"},{"key":"13230_CR16","doi-asserted-by":"crossref","unstructured":"Shahzad F, Shahzad F, Khan A, Waqar Z, Hafeez E, Shami B, et al. 2025 The Safety and Efficacy of Adjunctive Lacosamide for Partial-onset Seizures; a Meta-Analysis (P12\u20139.007). Neurology;104(7_Supplement_1)","DOI":"10.1212\/WNL.0000000000211118"},{"issue":"5","key":"13230_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.3540","volume":"14","author":"F Shahzad","year":"2024","unstructured":"Shahzad F, Ahmed U, Muhammad A, Shahzad F, Naufil SI, Sukkari MW et al (2024) Safety and efficacy of desmopressin (DDAVP) in preventing hematoma expansion in intracranial hemorrhage associated with antiplatelet drugs use: a systematic review and metaanalysis. Brain Behav 14(5):e3540","journal-title":"Brain Behav"},{"issue":"12","key":"13230_CR18","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1001\/jamaneurol.2015.2268","volume":"72","author":"RA Hauser","year":"2015","unstructured":"Hauser RA, Stocchi F, Rascol O, Huyck SB, Capece R, Ho TW et al (2015) Preladenant as an adjunctive therapy with levodopa in parkinson disease: two randomized clinical trials and lessons learned. JAMA Neurol 72(12):1491\u20131500","journal-title":"JAMA Neurol"},{"key":"13230_CR19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40035-018-0119-7","volume":"7","author":"Z Zhang","year":"2018","unstructured":"Zhang Z, Shao M, Chen S, Liu C, Peng R, Li Y et al (2018) Adjunct rasagiline to treat Parkinson\u2019s disease with motor fluctuations: a randomized, double-blind study in China. Transl Neurodegener 7:14","journal-title":"Transl Neurodegener"},{"issue":"8","key":"13230_CR20","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1002\/mds.25877","volume":"29","author":"RA Hauser","year":"2014","unstructured":"Hauser RA, Silver D, Choudhry A, Eyal E, Isaacson S, ANDANTE study investigators (2014) Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson\u2019s disease. Mov Disord 29(8):1028\u20131034","journal-title":"Mov Disord"},{"key":"13230_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.parkreldis.2020.04.012","volume":"75","author":"N Hattori","year":"2020","unstructured":"Hattori N, Tsuboi Y, Yamamoto A, Sasagawa Y, Nomoto M, ME2125-3 Study Group (2020) Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson\u2019s disease: a randomized, double-blind, placebo-controlled, phase II\/III study. Parkinsonism Relat Disord 75:17\u201323","journal-title":"Parkinsonism Relat Disord"},{"issue":"11","key":"13230_CR22","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s40263-022-00958-6","volume":"36","author":"Q Wei","year":"2022","unstructured":"Wei Q, Tan Y, Xu P, Tao E, Lu Z, Pan X et al (2022) The XINDI study: a randomized phase III clinical trial evaluating the efficacy and safety of safinamide as add-on therapy to levodopa in chinese patients with parkinson\u2019s disease with motor fluctuations. CNS Drugs 36(11):1217\u20131227","journal-title":"CNS Drugs"},{"issue":"7","key":"13230_CR23","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1017\/S1461145713000175","volume":"16","author":"L Zhang","year":"2013","unstructured":"Zhang L, Zhang Z, Chen Y, Qin X, Zhou H, Zhang C et al (2013) Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson\u2019s disease: a randomized, double-blind, parallel-controlled, multi-centre trial. Int J Neuropsychopharmacol 16(7):1529\u20131537","journal-title":"Int J Neuropsychopharmacol"},{"issue":"4","key":"13230_CR24","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1212\/01.WNL.0000134672.44217.F7","volume":"63","author":"F Stocchi","year":"2004","unstructured":"Stocchi F, Arnold G, Onofrj M, Kwiecinski H, Szczudlik A, Thomas A et al (2004) Improvement of motor function in early Parkinson disease by safinamide. Neurology 63(4):746\u2013748","journal-title":"Neurology"},{"issue":"2","key":"13230_CR25","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/archneur.62.2.241","volume":"62","author":"Parkinson Study Group","year":"2005","unstructured":"Parkinson Study Group (2005) A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62(2):241\u2013248","journal-title":"Arch Neurol"},{"issue":"1","key":"13230_CR26","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3233\/JPD-150700","volume":"6","author":"C Cattaneo","year":"2016","unstructured":"Cattaneo C, Sardina M, Bonizzoni E (2016) Safinamide as add-on therapy to levodopa in mid- to late-stage parkinson\u2019s disease fluctuating patients: post hoc analyses of studies 016 and SETTLE. J Parkinsons Dis 6(1):165\u2013173","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"13230_CR27","first-page":"23","volume":"4","author":"L Nayak","year":"2008","unstructured":"Nayak L, Henchcliffe C (2008) Rasagiline in treatment of Parkinson\u2019s disease. Neuropsychiatr Dis Treat 4(1):23\u201332","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"15","key":"13230_CR28","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P et al (2008) Movement disorder society-sponsored revision of the unified parkinson\u2019s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23(15):2129\u20132170","journal-title":"Mov Disord"},{"issue":"11","key":"13230_CR29","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s40263-023-01048-x","volume":"37","author":"L Aboulatta","year":"2023","unstructured":"Aboulatta L, Haidar L, Abou-Setta A, Askin N, Rabbani R, Lavu A et al (2023) Efficacy and safety of MAO-B inhibitors safinamide and zonisamide in parkinson\u2019s disease: a systematic review and meta-analysis of randomized controlled trials. CNS Drugs 37(11):941\u2013956","journal-title":"CNS Drugs"},{"issue":"2","key":"13230_CR30","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/mds.25751","volume":"29","author":"R Borgohain","year":"2014","unstructured":"Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Chirilineau D et al (2014) Randomized trial of safinamide add-on to levodopa in Parkinson\u2019s disease with motor fluctuations. Mov Disord 29(2):229\u2013237","journal-title":"Mov Disord"},{"key":"13230_CR31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.parkreldis.2018.04.025","volume":"53","author":"N Hattori","year":"2018","unstructured":"Hattori N, Takeda A, Takeda S, Nishimura A, Kato M, Mochizuki H et al (2018) Efficacy and safety of adjunctive rasagiline in Japanese Parkinson\u2019s disease patients with wearing-off phenomena: a phase 2\/3, randomized, double-blind, placebo-controlled, multicenter study. Parkinsonism Relat Disord 53:21\u201327","journal-title":"Parkinsonism Relat Disord"},{"key":"13230_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.866502","volume":"13","author":"J Kulisevsky","year":"2022","unstructured":"Kulisevsky J, Mart\u00ednez-Horta S, Campolongo A, Pascual-Sedano B, Mar\u00edn-Lahoz J, Bejr-Kasem H et al (2022) A randomized clinical trial to evaluate the effects of safinamide on apathetic non-demented patients with parkinson\u2019s disease. Front Neurol 13:866502","journal-title":"Front Neurol"},{"issue":"3","key":"13230_CR33","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s40262-016-0449-5","volume":"56","author":"T M\u00fcller","year":"2017","unstructured":"M\u00fcller T, Foley P (2017) Clinical pharmacokinetics and pharmacodynamics of safinamide. Clin Pharmacokinet 56(3):251\u2013261","journal-title":"Clin Pharmacokinet"},{"key":"13230_CR34","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.12688\/f1000research.21372.1","volume":"8","author":"AM Abdelalem Aziz","year":"2019","unstructured":"Abdelalem Aziz AM (2019) A systematic review and meta-analysis of safety and efficacy of safinamide for motor fluctuations in patients with Parkinson\u2019s disease. F1000Res 8:2078","journal-title":"F1000Res"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13230-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13230-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13230-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T00:14:54Z","timestamp":1757204094000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13230-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["13230"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13230-w","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"26 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors would like to declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Since this is a review article, ethical approval is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Since this is a review article of already published data, informed consent is waived.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"486"}}